and 2023. Conclusions: Antifungal resistance in non-albicans Candida species represents an emerging public health threat, however, within the Southeast region, ARLN data has shown a decreasing trend of azole resistance. This may be due in part to changes in reporting requirements and submission criteria from within the region. Nevertheless, C. tropicalis showed high resistance to azoles within the Southeast region. These Candida species should be monitored to inform clinical decision making and identify resistance patterns in other US regions due to their increase in resistance worldwide.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s89-s90 doi:10.1017/ash.2024.228

## **Presentation Type:**

Poster Presentation - Poster Presentation Subject Category: Emerging Pathogens Candida auris in the Healthcare Environment: Prevalence, Anti-Fungal Resistance, and Survival on Porous & Non-Porous Surfaces Brandon Smith, Environmental Safety Technologies, Inc. and Richard Miller, Environmental Safety Technologies, Inc.

Candida auris is an emerging multidrug-resistant pathogenic yeast capable of causing severe illness in the healthcare environment. It spreads easily amongst patient populations, is often resistant to anti-fungal treatments and can survive on surfaces for prolonged periods. In the current study, 85 sites within hospital settings were screened for surface-contaminated Candida species and C. auris. Surface swab samples were transferred to chromogenic agar media designed to isolate and identify Candida species and were incubated at 35°C for 48 hr. Samples were confirmed using molecular techniques designed to specifically target C. auris from other Candida species. Data was compiled to show prevalence of six key Candida species (C. albicans, C. auris, C. glabrata, C. krusei and C. tropicalis). Survivability on surfaces was performed using CDC B11903 C. auris strain. Plastic, metal and fabric surfaces used were purchased from a medical supply store. Once inoculated with 500 CFU/ml in sterile distilled water, the surfaces were kept in a Class II hood with minimal airflow and ambient conditions (21°C, 60% RH) and sampled daily. Results showed 25 of the 85 (29.4%) tested sites were positive for Candida species, with 3 of those sites positive for C. auris. Anti-fungal resistance among the three isolates (tested using concentration gradient test strips) showed notable resistance to fluconazole, but not to amphotericin B nor micafungin. C. auris survivability was dependent upon surface type, with the C. auris test strain surviving for 39 days on three different types of hospital curtains, and ≥10 days on a variety of non-porous plastic or metal surfaces. With demonstrated survivability of C. auris for long periods of time on hospital surfaces, it becomes critical for healthcare facilities to consider C. auris when developing infection prevention programs.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s90 doi:10.1017/ash.2024.229

## **Presentation Type:**

Poster Presentation - Poster Presentation Subject Category: Emerging Pathogens Hospital-Associated Transmission of Candida auris from Adult to **Pediatric Patient** 

Erin Barker, The Johns Hopkins Hospital; Vivian Donnelly, The Johns Hopkins Hospital; Susan Fallon, The Johns Hopkins Hospital; Sara Pau, The Johns Hopkins Hospital; Melanie Curless, The Johns Hopkins Hospital; Erica Prochaska, Johns Hopkins University; Shannon Murphy, Johns Hopkins University; Patricia Simner, Johns Hopkins University; Sean Zhang, Johns Hopkins School of Medicine; Aaron Milstone, Johns Hopkins University and Anna Sick-Samuels, Johns Hopkins School of Medicine

Background: Candida auris, an emerging multidrug-resistant fungus, is often difficult to control in hospital outbreaks. We report the hospital

**Presentation Type:** Poster Presentation - Poster Presentation Subject Category: Emerging Pathogens Epidemiology of Extrapulmonary Nontuberculous Mycobacterial Disease - 4 Emerging Infection Program Sites, 2021 Rebecca Byram, Centers for Disease Control and Prevention, Chenega Enterprise Systems and Solutions; Kelly Jackson, Centers for Disease Control and Prevention; Christopher Czaja, Colorado Department of Public Health and Environment; Helen Johnston, Colorado Department of Public Health and Environment; Devra Barter, Minnesota Department of Health; Ruth Lynfield, Minnesota Department of Health; Nathan Centurion, Minnesota Department of Health; Laura Tourdot, Minnesota Department of Health; Ghinwa Dumyati, University of Rochester Medical Center; Christopher Myers, NY Emerging Infections Program; Rebecca Pierce, Oregon Emerging Infections Program; Nadege Charles Toney, Oregon Emerging Infections Program; Adel Mansour, Oregon Emerging Infections Program; Shelley Magill, Centers for Disease Control and Prevention and Isaac See, Centers for Disease Control and Prevention


investigation and findings of a transmission of C. auris from patients hospitalized in an adult unit to a pediatric unit, the first in Maryland. Methods: Between June and September 2023, C. auris was recovered from two patients admitted to an adult Neuroscience Intensive Care Unit (ICU) and a patient admitted to a pediatric ICU. Infection control initiated an investigation involving staff interviews, observations and chart reviews. Cases were defined as any patient with clinical or surveillance cultures growing C. auris. Point prevalence surveillance was conducted by collecting nares and composite axilla/groin swabs from patients on the affected units. Environmental cultures collected using moistened E-Swabs (Copan, Murrieta, CA) from shared supplies were plated on CHROMagar Candida (BD, Sparks, MD). C. auris isolates from patients hospitalized at the facility between February 2022 and October 2023 were analyzed by WGS for relatedness. WGS was performed using Illumina NextSeq 300 bp paired-end sequencing (Illumina, San Diego, CA). Single nucleotide polymorphism (SNP) analysis was performed by comparing raw reads to the reference C. auris B8441 genome for subsequent clustering analysis (Ares Genetics, Vienna, Austria). Results: WGS demonstrated isolates from two adults and one pediatric patient were less than three SNPs different, suggesting a shared isolate. One additional pediatric case was identified from surveillance cultures collected from 27 patients. Investigation into possible transmission routes revealed healthcare personnel serving both units, specifically clinical teams and continuous electroencephalography (cEEG) technologists. Additionally, cEEG equipment was used on both adult and pediatric patients and twelve equipment surface swabs and three samples each of measuring tape and gel were collected. C. auris was not isolated, however sensitivity of environmental sampling is unclear and suspicion for possible fomite/environmental transmission persisted. Other possible transmission routes included gaps in hand hygiene, isolation, disinfection of shared equipment, and reuse of single-use items. Interventions included improving and monitoring infection prevention practices, educating multi-disciplinary personnel and heightened environmental cleaning. Conclusion: This case highlights the feasibility of transmission of C. auris between patients admitted to a geographically distant unit. Our investigation revealed multiple possible routes of transmission including direct contact (from healthcare personnel or equipment) or indirect environmental sources. Prevention of hospital-associated C. auris transmission likely necessitates meticulous adherence to hand hygiene, contact precautions, and careful cleaning and disinfection of patient environments and equipment used by all disciplines.

Disclosure: Patricia Simner: Research Contracts: BD Diagnostics, OpGen Inc., Qiagen Sciences Inc, T2 Diagnostics, Accelerate Diagnostics; Research Collaborators: Ares Genetics, CosmosID, IDbyDNA, Illumina; Consulting: OpGen Inc., BD Diagnostics, Shionogi Inc., GeneCapture, Qiagen Sciences Inc, Entasis, Day Zero Diagnostics, Next Gen Diagnostics

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s90 doi:10.1017/ash.2024.230

Background: Extrapulmonary nontuberculous mycobacteria (ENTM) infections are difficult to treat and often require prolonged therapy or surgery. Few population-based studies describe ENTM epidemiology, though well-known healthcare-associated outbreaks have occurred. Using the first year of multi-site ENTM surveillance, we characterized rates and how frequently ENTM infections may be related to healthcare. Methods: CDC's Emerging Infections Program conducted active, laboratory- and population-based surveillance for ENTM cases in 4 sites (Colorado [5 counties], Minnesota [statewide], New York [1 county], and Oregon [statewide]) in 2021. An incident ENTM case was NTM isolation from a non-pulmonary specimen, excluding stool or rectal swabs, in a resident of the surveillance area without either medical record documentation of prior ENTM infection or isolation of ENTM in the prior 12 months. Demographic, clinical, information on selected healthcare and community exposures, and laboratory data were collected via medical record review. We calculated incidence per 100,000 population using U.S. Census population estimates and performed descriptive analyses. Results: A total of 180 incident ENTM cases were reported in 2021. The crude annual incidence rate was 1.3 per 100,000 persons. Incidence increased with age (from 0.95 per 100,000 among 0–17 year-olds to 2.65 per 100,000 among persons  $\geq$ 65), ranged from 0.8 among non-Hispanic Asian persons to 1.6 per 100,000 in non-Hispanic Black persons, and was similar among males (1.3 per 100,000) and females (1.4 per 100,000; Figure 1). Mycobacterium avium complex (64 [35.6%]) was the most frequently isolated species group, followed by Mycobacterium chelonae complex (31 [17.2%]). Skin and soft tissue infections were the most frequent infection type (37 [20.6%]); 27 cases (15.0%) were associated with disseminated and/or only bloodstream infection, and 56 cases (31.1%) had no infection type documented. Among 93 cases with localized ENTM infections (i.e., infections that were not disseminated and/or only bloodstream infections), 38.7% had only healthcare-related exposures, 14% had only community-related exposures and 6.5% had both exposure types at the site of infection (Figure 2). Healthcare-related exposures at the infection site included surgery (23.7%), injection/infusion (21.5%), and medical devices (18.3%). The


Figure 1. Incident ENTM (N=180) Case Rates by Age, Sex at Birth, and Race/Ethnicity, Emerging Infections Program, 2021



Race/Ethnicity

\*Cases where the race of the person was unknown were assigned a race based on the distribution of known race among cases by age, ethnicity, gender, and EIP site.
\*Cases where the ethnicity of the person was unknown were assigned ethnicity based on the distribution of known

"Cases where the ethnicity of the person was unknown were assigned ethnicity based on the distribution of known ethnicity among cases by age, race, gender, and EIP site. Figure 2. Exposures among ENTM Cases with Localized Infections<sup>a</sup> (n=93), Emerging Infections Program, 2021



<sup>a</sup> Excludes incident cases with no infection type (n=56); unknown infection type (n=4); and cases either with bloodstream infection and no other infection types documented or with disseminated infection (n=27)

most frequent community-related exposure at the infection site was trauma (17.2%). Only one case was part of a known outbreak, which was healthcare-associated. **Conclusions:** ENTM infections are relatively rare, but nearly half of patients with localized ENTM infections had prior healthcare-related exposures. This indicates that the burden of ENTM infections related to healthcare may be much larger than what has been suggested from reported outbreaks.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s90-s91 doi:10.1017/ash.2024.231

### **Presentation Type:**

Poster Presentation - Poster Presentation Subject Category: Emerging Pathogens

# Prevalence of Candida auris Among High-Risk Patients at a Comprehensive Cancer Center

Adina Feldman, MD Anderson Cancer Center; Micah Bhatti, MD Anderson Cancer Center; Jane Powell, MD Anderson Cancer Center; Amy Spallone, The University of Texas MD Anderson Cancer Center and Roy Chemaly, The University of Texas MD Anderson Cancer Center

Background: Candida auris (C. auris) is a multidrug-resistant fungus that is increasingly implicated in outbreaks in healthcare facilities worldwide. The Centers for Disease Control and Prevention (CDC) and the Texas Department of State Health Services recommend healthcare facilities screen patients who are considered high-risk for C. auris, including patients with an overnight stay in a healthcare facility outside the United States (U.S.) in the previous year, or recently stayed in a rehabilitation (rehab) facility, long-term acute care (LTAC), or skilled nursing facility (SNF). Screening patients for C. auris colonization allows for early implementation of infection control measures, preventing transmission to healthcare workers and other patients. According to the CDC, most cases of C. auris result from local spread within and among healthcare facilities in the same city or state. In Texas, 160 clinical cases have been reported during the past 12 months. At present, the necessity of screening high-risk patients at our center for C. auris is not known. We aimed to determine the prevalence of C. auris colonization among our patient population. Method: During a 4-week period, we performed targeted screening of patients meeting the CDC's high-risk definition for C. auris. Admitted patients were screened by an Infection Preventionist (IP) using the electronic health record to identify patients who were either international or admitted from a rehab or care facility. A composite swab of bilateral axilla and groin creases was collected using an eSwab™ (Becton Dickinson) and sent to a reference lab (Mayo Clinic Laboratories) for polymerase chain reaction (PCR)-based detection of C. auris. Additionally, we reviewed historic cases of C. auris diagnosed at our institution to better define our at-risk patients. Results: Between July 14 - August 8, 2023, we consecutively screened 25 high-risk patients, including 18 (72%) international and 7 (28%) patients from rehabs, LTAC, or SNF. None were positive for C. auris.